Fernando Velayos

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Managing risks of neoplasia in inflammatory bowel disease
    Fernando Velayos
    University of California, San Francisco, Center for Crohn s and Colitis, San Francisco, CA 94115, USA
    Curr Gastroenterol Rep 14:174-80. 2012
  2. ncbi Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system
    Fernando S Velayos
    Division of Gastroenterology, Department of Internal Medicine, University of California, San Francisco 94115, USA
    Gastroenterology 139:1511-8. 2010
  3. ncbi Colon cancer surveillance in inflammatory bowel disease patients: current and emerging practices
    Fernando Velayos
    University of California, San Francisco, Center for Crohn s and Colitis, 2330 Post Street, Suite 610, San Francisco, CA 94116, USA
    Expert Rev Gastroenterol Hepatol 2:817-25. 2008
  4. ncbi Management of steroid-dependent ulcerative colitis: immunomodulatory agents, biologics, or surgery?
    Fernando Velayos
    Center for Colitis and Crohn s Disease, University of California, San Francisco, California 94118, USA
    Clin Gastroenterol Hepatol 5:668-71. 2007
  5. ncbi Positioning biologic therapy for Crohn's disease and ulcerative colitis
    Fernando S Velayos
    Center for Crohn s and Colitis, University of California, San Francisco, 2330 Post Street Suite 610, San Francisco, California 94115, USA
    Curr Gastroenterol Rep 9:521-7. 2007
  6. ncbi Colonoscopy after CT diagnosis of diverticulitis to exclude colon cancer: a systematic literature review
    Victor F Sai
    Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94143, USA
    Radiology 263:383-90. 2012
  7. ncbi Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates
    Joel H Rubenstein
    The Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Am J Gastroenterol 104:2222-32. 2009
  8. ncbi Colorectal cancer screening and surveillance in the elderly patient
    Lukejohn W Day
    Division of Gastroenterology, San Francisco General Hospital, San Francisco, California, USA
    Am J Gastroenterol 106:1197-206;quiz 1207. 2011
  9. ncbi Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease
    Fernando S Velayos
    Division of Gastroenterology and Hepatology, University of California, San Francisco, California, USA
    Inflamm Bowel Dis 10:657-60. 2004
  10. ncbi Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study
    Fernando S Velayos
    Division of Gastroenterology and Hepatology, University of California San Francisco, San Francisco, California, USA
    Gastroenterology 130:1941-9. 2006

Detail Information

Publications16

  1. ncbi Managing risks of neoplasia in inflammatory bowel disease
    Fernando Velayos
    University of California, San Francisco, Center for Crohn s and Colitis, San Francisco, CA 94115, USA
    Curr Gastroenterol Rep 14:174-80. 2012
    ..Physicians and health professionals may find this information useful for counseling and educating patients as well as for improving patient care...
  2. ncbi Prevalence of colorectal cancer surveillance for ulcerative colitis in an integrated health care delivery system
    Fernando S Velayos
    Division of Gastroenterology, Department of Internal Medicine, University of California, San Francisco 94115, USA
    Gastroenterology 139:1511-8. 2010
    ..Limited data are available on rates of colonoscopy surveillance and factors associated with surveillance...
  3. ncbi Colon cancer surveillance in inflammatory bowel disease patients: current and emerging practices
    Fernando Velayos
    University of California, San Francisco, Center for Crohn s and Colitis, 2330 Post Street, Suite 610, San Francisco, CA 94116, USA
    Expert Rev Gastroenterol Hepatol 2:817-25. 2008
    ..This article reviews the current practice and emerging technologies for detecting and preventing colon cancer in patients with IBD...
  4. ncbi Management of steroid-dependent ulcerative colitis: immunomodulatory agents, biologics, or surgery?
    Fernando Velayos
    Center for Colitis and Crohn s Disease, University of California, San Francisco, California 94118, USA
    Clin Gastroenterol Hepatol 5:668-71. 2007
  5. ncbi Positioning biologic therapy for Crohn's disease and ulcerative colitis
    Fernando S Velayos
    Center for Crohn s and Colitis, University of California, San Francisco, 2330 Post Street Suite 610, San Francisco, California 94115, USA
    Curr Gastroenterol Rep 9:521-7. 2007
    ....
  6. ncbi Colonoscopy after CT diagnosis of diverticulitis to exclude colon cancer: a systematic literature review
    Victor F Sai
    Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94143, USA
    Radiology 263:383-90. 2012
    ..To estimate the prevalence of underlying adenocarcinoma of the colon in patients in whom acute diverticulitis was diagnosed at computed tomography (CT) and to compare that to the prevalence of colon cancer in the general population...
  7. ncbi Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates
    Joel H Rubenstein
    The Division of Gastroenterology, Department of Internal Medicine, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Am J Gastroenterol 104:2222-32. 2009
    ..Therefore, in patients prescribed 5-ASAs for maintenance of remission, annual surveillance might be overly burdensome and inefficient. We aimed to determine the ideal frequency of surveillance in patients with UC maintained on 5-ASAs...
  8. ncbi Colorectal cancer screening and surveillance in the elderly patient
    Lukejohn W Day
    Division of Gastroenterology, San Francisco General Hospital, San Francisco, California, USA
    Am J Gastroenterol 106:1197-206;quiz 1207. 2011
    ..This review addresses the factors unique to colorectal cancer and performing colonoscopy in older adults that are relevant in weighing the risks and benefits of screening and surveillance in this population...
  9. ncbi Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease
    Fernando S Velayos
    Division of Gastroenterology and Hepatology, University of California, San Francisco, California, USA
    Inflamm Bowel Dis 10:657-60. 2004
    ..Mechanisms by which azathioprine and infliximab may impair the natural defense mechanisms against Pneumocystis are discussed...
  10. ncbi Predictive and protective factors associated with colorectal cancer in ulcerative colitis: A case-control study
    Fernando S Velayos
    Division of Gastroenterology and Hepatology, University of California San Francisco, San Francisco, California, USA
    Gastroenterology 130:1941-9. 2006
    ..A history of postinflammatory pseudopolyps appears to be a predictive factor for cancer...
  11. ncbi Durability of infliximab dose intensification in Crohn's disease
    Kirk K Lin
    Division of Gastroenterology, Department of Internal Medicine, University of California at San Francisco, San Francisco, CA, USA
    Dig Dis Sci 57:1013-9. 2012
    ..Dose intensification is a common approach to treat Crohn's disease (CD) patients who lose response to infliximab maintenance therapy. Few studies have reported upon its long-term efficacy or predictors of response...
  12. ncbi Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies
    Fernando S Velayos
    Division of Gastroenterology and UCSF Center for Colitis and Crohn's Disease, University of California, San Francisco, California 94143, USA
    Am J Gastroenterol 100:1345-53. 2005
    ..Additional studies analyzing the effect of 5-ASA on risk of dysplasia are needed...
  13. ncbi Low rate of microsatellite instability in young patients with adenomas: reassessing the Bethesda guidelines
    Fernando S Velayos
    Division of Gastroenterology and Colorectal Cancer Prevention Program, University of California, San Francisco, CA, USA
    Am J Gastroenterol 100:1143-9. 2005
    ..New strategies that improve on the current clinical and molecular screening methods should be developed so that at-risk individuals can be identified and referred for germline testing before developing their first cancer...
  14. ncbi Incidence and prognosis of colorectal dysplasia in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota
    Tine Jess
    Department of Medical Gastroenterology, Herlev University Hospital, Herlev, Denmark
    Inflamm Bowel Dis 12:669-76. 2006
    ..CONCLUSIONS: This population-based cohort study from Olmsted County, Minnesota did not confirm an increased risk of cancer related to fLGD, whereas 22% of patients with ALMs in areas of IBD developed fLGD or DALMs...
  15. ncbi Risk of intestinal cancer in inflammatory bowel disease: a population-based study from olmsted county, Minnesota
    Tine Jess
    Department of Medical Gastroenterology, Herlev University Hospital, Herlev, Denmark
    Gastroenterology 130:1039-46. 2006
    ..The colorectal cancer risk was increased slightly among Crohn's disease patients, who also had a 40-fold excess risk for small-bowel cancer...
  16. ncbi Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis
    Gary R Lichtenstein
    Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
    Rev Gastroenterol Disord 8:21-30; quiz 31-2. 2008
    ..Novel formulations of mesalamine and newly devised, high-dose regimens offer additional therapeutic options and may lead to improved treatment adherence, longer-lasting periods of remission, and enhanced patient well-being...